Krishna Institute of Medical Sciences (KIMS) saw revenue climb in FY26. However, profits declined at both standalone and consolidated levels. The consolidated net debt-to-equity ratio increased significantly to 141%.

KIMS Financials: FY26 Revenue Grows, Profit Declines Amid Rising Debt

Consolidated Revenue: ₹3,904.6 crore
Consolidated Profit: ₹242.0 crore

Reader Takeaway: Revenue growth is positive, but declining profits and high leverage need monitoring.

What just happened

Krishna Institute of Medical Sciences Ltd (KIMS) announced its financial results for the year ended March 31, 2026. Consolidated revenue rose to ₹3,904.6 crore from ₹3,035.1 crore in the previous fiscal. However, consolidated profit saw a significant drop to ₹242.0 crore, down from ₹414.8 crore a year ago. Standalone revenue also increased to ₹1,701.5 crore from ₹1,384.1 crore, but standalone profit decreased to ₹260.7 crore from ₹302.9 crore.

The company's consolidated net debt-to-equity ratio increased substantially to 141% as of March 31, 2026, up from 86% in the prior year. KIMS also completed acquisitions, including a 100% stake in Chalasani Hospitals Private Limited in August 2024 and a 51% stake in MEDA Institute of Podiatry Private Limited in June 2024.

Why this matters

The revenue growth indicates continued business expansion, but the decline in profitability suggests margin pressures or increased operating costs. The sharp rise in the debt-to-equity ratio highlights increased financial leverage, which could pose a risk if not managed effectively against future earnings.

The backstory

KIMS has been expanding its operations and acquired several entities in recent years, aiming to strengthen its market position. The results reflect the financial outcomes of these growth strategies and integration efforts.

What changes now

Investors will be watching how KIMS manages its increased debt levels and integrates its recent acquisitions. Profitability trends and the effectiveness of cost management will be crucial for future performance.

Risks to watch

Increased leverage poses a risk to financial stability if revenue growth falters or margins compress further. The auditors flagged the impairment assessment of investments and goodwill as key audit matters, indicating areas requiring close scrutiny.

Peer comparison

While specific peer data is not provided in the filing, the healthcare sector often sees companies balancing expansion with profitability. KIMS's current performance with rising debt and falling profits might differ from peers focused on leaner operations or higher margins.

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹3,904.6 crore (vs. ₹3,035.1 crore FY25)
• Consolidated Profit FY26: ₹242.0 crore (vs. ₹414.8 crore FY25)
• Standalone Revenue FY26: ₹1,701.5 crore (vs. ₹1,384.1 crore FY25)
• Standalone Profit FY26: ₹260.7 crore (vs. ₹302.9 crore FY25)
• Consolidated Net Debt-to-Equity FY26: 141% (vs. 86% FY25)

What to track next

Focus on KIMS's quarterly results, management commentary on margin improvement, debt reduction strategies, and the performance of acquired entities.